The company said stockholders approved an amendment to its certificate of incorporation at its annual meeting on June 20, 2024 to allow exculpation of certain officers to the extent permitted by Delaware law. The vote was 103,146,578 for and 16,274,796 against.

1. 01

   The company said stockholders approved an amendment to its certificate of incorporation at its annual meeting on June 20, 2024 to allow exculpation of certain officers to the extent permitted by Delaware law. The vote was 103,146,578 for and 16,274,796 against.

2. 02

   The company said its stockholders elected 9 nominees to the Board of Directors to serve terms of 1 year until the 2025 annual meeting of stockholders. Christopher A. Viehbacher received 118,593,483 votes for and 886,743 against, and Caroline D. Dorsa received 87,883,981 votes for and 31,591,984 against.

3. 03

   The company said stockholders approved the selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024, with 123,728,418 votes for and 5,348,316 against. The advisory vote on executive compensation was approved with 114,367,799 votes for and 5,054,473 against.

4. 04

   The company said stockholders approved the Biogen Inc. 2024 Omnibus Equity Plan with 112,726,169 votes for and 6,693,956 against, and the Biogen Inc. 2024 Employee Stock Purchase Plan with 119,064,435 votes for and 413,475 against.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.